Dianthus Therapeutics (DNTH) Set to Release Earnings on Thursday

Dianthus Therapeutics (NASDAQ:DNTH) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.9445) per share and revenue of $0.46 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. On average, analysts expect Dianthus Therapeutics to post ($3.81) EPS for the current fiscal year and ($4.74) EPS for the next fiscal year.

Dianthus Therapeutics Stock Up 3.5%

NASDAQ DNTH opened at $82.31 on Thursday. The stock has a market cap of $4.51 billion, a P/E ratio of -19.83 and a beta of 1.35. The company’s 50-day simple moving average is $93.92 and its 200 day simple moving average is $84.17. Dianthus Therapeutics has a twelve month low of $32.28 and a twelve month high of $117.88.

Analyst Ratings Changes

Several analysts recently commented on DNTH shares. Roth Capital assumed coverage on Dianthus Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $113.00 price target on the stock. Wedbush increased their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Raymond James Financial restated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Truist Financial upped their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Dianthus Therapeutics in a report on Friday, September 11th. They set an “overweight” rating and a $135.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $128.54.

Insider Activity

In other Dianthus Therapeutics news, CAO Edward Carr sold 20,000 shares of the stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $101.38, for a total value of $2,027,600.00. Following the transaction, the chief accounting officer directly owned 20,000 shares in the company, valued at approximately $2,027,600. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Adam Veness sold 16,167 shares of Dianthus Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the completion of the sale, the senior vice president directly owned 3,833 shares of the company’s stock, valued at $423,086.54. This trade represents a 80.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 242,429 shares of company stock worth $26,118,913. 3.02% of the stock is owned by company insiders.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.